Will inter partes review speed US generic drug entry?

Nat Biotechnol. 2017 Dec 8;35(12):1139-1141. doi: 10.1038/nbt.4036.

Authors

Jonathan J Darrow¹, Reed F Beall¹, Aaron S Kesselheim¹

Affiliation

¹ Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

PMID: 29220017
DOI: 10.1038/nbt.4036

No abstract available

MeSH terms

Drug Industry / legislation & jurisprudence*
Drugs, Generic* / economics
Drugs, Generic* / supply & distribution
Humans
Patents as Topic / legislation & jurisprudence*
United States

Substances

Drugs, Generic